Carolina Reduzzi, Chief Operating Officer & Treasurer at Precision Medicine Action for Cancer (PMAC) and Director of Cristofanilli CTC laboratory at Weill Cornell Medicine, shared a post by Precision Medicine Action for Cancer, adding:
“After months of preparation, I couldn’t be happier to share this moment!
Launching Precision Medicine Action for Cancer (PMAC) as a non-profit it’s the start of a journey I deeply believe in.
There’s an exciting path ahead, and I’m grateful to everyone who has supported this vision and the amazing researchers that are making this possible. The best is yet to come!”
Quoting Precision Medicine Action for Cancer (PMAC)‘s post:
“We are thrilled to announce the official launch of Precision Medicine Action for Cancer (PMAC) as a non-profit organization!
Our mission is:
- Build a clinical and molecular annotated database to produce real-world evidence on liquid biopsy use in cancer care
- Educate the next generation of investigators and the broader community on liquid biopsy for precision medicine
- Improve care and prognosis for patients with breast cancer and other solid tumors
Discover more about our vision, research, and opportunities to collaborate.”
More from Carolina Reduzzi on OncoDaily.